Eli Lilly to Acquire Centessa Pharmaceuticals for up to $7.8 Billion

Eli Lilly Agrees to Acquire Centessa Pharmaceuticals in $7.8 Billion Deal

Eli Lilly & Co. has agreed to purchase Centessa Pharmaceuticals Plc in a deal worth up to $7.8 billion, marking the company's expansion into treatments for sleep disorders. This strategic move is part of Lilly's efforts to enhance its portfolio and address the growing demand for novel therapies in the sleep-wake disorder market.

Under the terms of the agreement, Lilly will pay $38 per share for Centessa, with the potential for an additional $9 payment if three milestone targets are met. This valuation represents a 70% premium to Centessa's closing price on Monday. The upfront payment is valued at approximately $6.3 billion, with an additional $1.5 billion in potential payments contingent upon the successful achievement of these milestones.

Centessa Pharmaceuticals is currently developing a range of drugs aimed at treating sleep-wake disorders, including narcolepsy. While existing treatments for sleep conditions are available, they often come with unwanted side effects, such as dependency and a hangover-like effect the next day. By acquiring Centessa, Lilly aims to leverage the company's expertise in developing innovative treatments for sleep disorders, ultimately providing patients with more effective and safer alternatives.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Note: The table above highlights the key terms of the acquisition, including the price per share and the premium to Centessa's closing price on Monday.